Stryker (NYSE: SYK) is a large medical technology company that develops and sells a range of products, including implants used in joint replacement and trauma surgeries. With a market capitalization of approximately $112.88 billion, it is a major player in the healthcare sector. The company's stock price recently saw a significant daily drop of 6.47% to $294.73.
On May 1, 2026, the investment firm Goldman Sachs raised its price target on Stryker to $361 from $357. A price target is an analyst's projection of a stock's future price. At the same time, the firm maintained its "Neutral" rating, which suggests that it expects the stock to perform in line with the market.
The neutral stance reflects the company's mixed first-quarter 2026 results, which were impacted by a major cyber incident. As highlighted by Zacks, Stryker's adjusted earnings per share (EPS) of $2.60 missed analyst estimates of $2.98. EPS is a measure of a company's profit allocated to each outstanding share of stock.
Despite the earnings miss, the higher price target is supported by some positive signs. The company’s total revenues are $6.02 billion, a 2.6% increase from the previous year. Stryker also reports a worldwide organic sales growth of 2.4% and maintains its full-year financial forecast, showing confidence in its business.
Stryker's strategic moves also provide a basis for optimism. The company reports a record quarter for its Mako robotic system installations. Furthermore, as mentioned in its earnings call, Stryker is acquiring Amplitude Vascular Systems to expand its cardiovascular business and is launching a new Ortho Tech business to drive innovation.
